AR121036A1 - Compuesto para el secuestro de anticuerpos no deseables en un paciente - Google Patents

Compuesto para el secuestro de anticuerpos no deseables en un paciente

Info

Publication number
AR121036A1
AR121036A1 ARP200100819A ARP200100819A AR121036A1 AR 121036 A1 AR121036 A1 AR 121036A1 AR P200100819 A ARP200100819 A AR P200100819A AR P200100819 A ARP200100819 A AR P200100819A AR 121036 A1 AR121036 A1 AR 121036A1
Authority
AR
Argentina
Prior art keywords
compound
peptide
sequestration
patient
antibodies
Prior art date
Application number
ARP200100819A
Other languages
English (en)
Original Assignee
Ablevia Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablevia Biotech Gmbh filed Critical Ablevia Biotech Gmbh
Publication of AR121036A1 publication Critical patent/AR121036A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente proporciona un compuesto para el secuestro de anticuerpos no deseables (por ejemplo, relacionados con una enfermedad autoinmune) en un paciente. El compuesto comprende un andamio de biopolímero inerte y al menos un primer péptido n-mer de la fórmula general P(– S – P)₍ₙ₋₁₎ y un segundo péptido n-mer de la fórmula general P(– S – P)₍ₙ₋₁₎; en donde, independientemente de cada aparición, P es un péptido con una longitud de secuencia de 2 - 13 aminoácidos y S es un espaciador no peptídico, en donde, independientemente para cada uno de los péptidos n-mers, n es un número entero de al menos 1, en donde cada uno de los péptidos n-mers está unido al andamio de biopolímero. También se proporcionan composiciones farmacéuticas que comprenden el compuesto, así como un método para secuestrar uno o más anticuerpos presentes en un individuo y un método para inhibir una reacción inmune para un tratamiento con un agente activo.
ARP200100819A 2019-03-23 2020-03-25 Compuesto para el secuestro de anticuerpos no deseables en un paciente AR121036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19164784.1A EP3715374A1 (en) 2019-03-23 2019-03-23 Compound for the sequestration of undesirable antibodies in a patient

Publications (1)

Publication Number Publication Date
AR121036A1 true AR121036A1 (es) 2022-04-13

Family

ID=65991526

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100819A AR121036A1 (es) 2019-03-23 2020-03-25 Compuesto para el secuestro de anticuerpos no deseables en un paciente

Country Status (17)

Country Link
US (1) US20220062435A1 (es)
EP (3) EP3715374A1 (es)
JP (1) JP2022528736A (es)
KR (1) KR20210142615A (es)
CN (1) CN113631581A (es)
AR (1) AR121036A1 (es)
AU (1) AU2020249341A1 (es)
BR (1) BR112021018171A2 (es)
CA (1) CA3130187A1 (es)
DK (1) DK3898702T3 (es)
EA (1) EA202192085A1 (es)
ES (1) ES2927642T3 (es)
IL (1) IL286589A (es)
MX (1) MX2021011635A (es)
SG (1) SG11202108756TA (es)
TW (1) TW202102520A (es)
WO (1) WO2020193486A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986536B2 (en) * 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
KR20230074775A (ko) * 2020-09-23 2023-05-31 아블레비아 바이오테크 게엠베하 바이러스 벡터의 효능 증가를 위한 화합물
TW202228784A (zh) * 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5372933A (en) 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US7888458B1 (en) 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
WO2000033887A2 (en) 1998-12-08 2000-06-15 La Jolla Pharmaceutical Company Methods and formulations for reducing circulating antibodies
WO2004067549A2 (de) 2003-01-31 2004-08-12 Max-Delbrück-Centrum für Molekulare Medizin Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung
WO2004089422A2 (en) 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US8210547B2 (en) 2009-06-16 2012-07-03 Toyota Motor Engineering & Manufacturing North America, Inc. Active magneto-rheological spring assemblies and vehicle suspension systems incorporating the same
JP2013523179A (ja) 2010-04-13 2013-06-17 メディミューン，エルエルシー フィブロネクチンタイプｉｉｉドメインに基づく多量体足場
EP2402016A1 (en) 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor
JP4857396B1 (ja) 2011-04-13 2012-01-18 日本製薬株式会社 融合蛋白質
WO2015056713A1 (ja) 2013-10-15 2015-04-23 国立大学法人東京大学 ｃ－Ｍｅｔタンパク質アゴニスト
PT3116887T (pt) 2014-03-13 2021-04-30 Univ Basel Ligantes de hidratos de carbono que se ligam a anticorpos igm contra a glicoproteína associada à mielina
WO2015181393A1 (en) * 2014-05-30 2015-12-03 Per-Johan Jakobsson Novel sfti and cyclotide based peptides
EP2982756A1 (en) 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases
US11091591B2 (en) 2015-09-16 2021-08-17 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
KR102194188B1 (ko) 2015-11-18 2020-12-24 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
LT3472207T (lt) 2016-06-20 2021-05-10 F-Star Delta Limited Surišančios molekulės, kurios suriša pd-l1 ir lag-3
WO2018102668A1 (en) 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies

Also Published As

Publication number Publication date
EP3960769A1 (en) 2022-03-02
WO2020193486A1 (en) 2020-10-01
AU2020249341A1 (en) 2021-11-18
CA3130187A1 (en) 2020-10-01
MX2021011635A (es) 2022-01-04
CN113631581A (zh) 2021-11-09
SG11202108756TA (en) 2021-10-28
ES2927642T3 (es) 2022-11-08
JP2022528736A (ja) 2022-06-15
IL286589A (en) 2021-12-01
US20220062435A1 (en) 2022-03-03
DK3898702T3 (da) 2022-09-26
EP3898702B1 (en) 2022-06-29
KR20210142615A (ko) 2021-11-25
BR112021018171A2 (pt) 2021-11-16
EP3898702A1 (en) 2021-10-27
EA202192085A1 (ru) 2021-12-10
TW202102520A (zh) 2021-01-16
EP3715374A1 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
AR121036A1 (es) Compuesto para el secuestro de anticuerpos no deseables en un paciente
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
EA201100927A1 (ru) Циклические аналоги 4-амино-4-оксобутаноил-пептидов, ингибиторы репликации вирусов
CY1122125T1 (el) Υποκατεστημενοι νουκλεοζιτες, νουκλεοτιδια και αναλογα αυτων
DOP2013000172A (es) Composicion farmaceutica
CL2019003324A1 (es) Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745)
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
CY1115526T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
BR112013003101A2 (pt) inibidores do vírus da hepatite c
CO6270303A2 (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
ECSP044933A (es) Método y montaje para aumentar el volumen del cabello
DOP2022000293A (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
BR112013020042A2 (pt) inibidores de vírus da hepatite c
PH12019500954A1 (en) Vaccine against porcine parvovirus
BR112022018067A2 (pt) Aminas de pirrolopirimidina como inibidores de complemento
MX2019005775A (es) Formulacion farmaceutica parenteral que contiene acido carglumico.
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
AR042910A1 (es) Compuestos de pirazolopirimidina y procedimiento para preparar el mismo y composiciones farmaceuticas que los contienen
MX2023003377A (es) Compuesto para aumentar la eficacia de los vectores virales.
BR112021014640A8 (pt) Sais de sulcardina
DOP2010000117A (es) Producto de dispersion solida de drogas basadas en n-aril urea
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
AR048957A1 (es) Derivados ciclopeptidos dotados de actividad anti-integrina.
BR112022001866A2 (pt) Derivados de amida híbridos de anfotericina b
EA201890160A1 (ru) Твердые фармацевтические композиции для лечения вируса гепатита с